Alessandro Gronchi, MD, president, Connective Tissue Oncology Society (CTOS), discusses some of the exciting data that will be presented at the 21st annual CTOS meeting in Lisbon, Portugal.
Tiragolumab/Atezolizumab for NSCLC Fails to Meet End Points in SKYSCRAPER-06
July 11th 2024The SKYSCRAPER-06 trial for the first-line treatment of non–small cell lung cancer was stopped because the combination of tiragolumab and atezolizumab did not improve survival compared with the control of pembrolizumab and chemotherapy.
Read More